Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CSK | P41240 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19573625 | 0.90 | BTK (0.56) | BTKTNK2 | |
| SCHEMBL15472812 | 0.88 | BTK (0.60) | BTK | |
| SCHEMBL15472813 | 0.87 | BTK (0.62) | BTK | |
| SCHEMBL15472821 | 0.87 | BTK (0.62) | BTK | |
| SCHEMBL28503533 | 0.85 | BTK (0.56) | BTK | |
| SCHEMBL28503534 | 0.85 | BTK (0.56) | BTK | |
| SCHEMBL19573548 | 0.84 | BTK (0.49) | BTK | |
| SCHEMBL24197246 | 0.82 | BTK (0.71) | BTKFGRFLT3CSKBLK | |
| SCHEMBL17060007 | 0.81 | BTK (0.66) | BTKFGRFLT3CSKBLK | |
| SCHEMBL15756452 | 0.81 | BTK (0.57) | BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885TNK2 189/4885FGR 204/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | BTK 1/4885TNK2 189/4885FGR 204/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885TNK2 189/4885FGR 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.